Drugmaker
The deal is worth $137 per share - a premium of 29 percent to FMI’s closing price on Monday - valuing the Cambridge, Massachusetts-based company at $5.3 billion.
The German drugmaker had received all required approvals from regulatory authorities, it said in a statement on Monday.
Most Read